San Francisco, United States
Provenance Bio is carving a niche within the alternative proteins sector, focusing on next-gen synthetic biology to rival traditional animal proteins. Under the mantra "Engineering the future of protein," they aim to propel advancements across beauty, nutrition, and materials via precision fermentation.
Founded in 2016 by Michalyn Andrews, Dr. Zev Gartner, Dr. John Dueber, and Christian Ewton, the company is redefining protein production with a unique patent-pending platform, chiefly for producing full-length collagen. Their innovations hold potential for transformative B-to-B applications across pharma, materials, and food sectors.
With no disclosed headquarters or recent investment details, Provenance Bio represents a forward-thinking prospect for investors eager to back pioneering biotechnology that promises to lead the commercial market shift away from traditional animal-derived proteins.
